ERGOMED PLC (2EM.DE) Stock Price, Forecast & Analysis
Europe - Frankfurt Stock Exchange - FRA:2EM - GB00BN7ZCY67 - Common Stock
2EM.DE Key Statistics, Chart & Performance
The current stock price of 2EM.DE is 11 EUR. In the past month the price decreased by -24.66%. In the past year, price decreased by -36.96%.
2EM.DE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| 56S1.DE | SARTORIUS STEDIM BIOTECH | 51.25 | 21.50B | ||
| DIM.PA | SARTORIUS STEDIM BIOTECH | 49.72 | 20.86B | ||
| SRT3.DE | SARTORIUS AG-VORZUG | 56.43 | 19.27B | ||
| SRT.DE | SARTORIUS AG | 43.51 | 14.86B | ||
| QIA.DE | QIAGEN N.V. | 20.31 | 8.94B | ||
| 1SXP.DE | SCHOTT PHARMA AG& CO KGAA | 15.87 | 2.32B | ||
| EVT.DE | EVOTEC SE | N/A | 2.24B | ||
| GXI.DE | GERRESHEIMER AG | 7.47 | 952.61M | ||
| FF.MI | FINE FOODS & PHARMACEUTICALS | 10.43 | 204.72M | ||
| ALECR.PA | EUROFINS CEREP-REGR | 24.9 | 178.00M | ||
| MLC.I | MALIN CORP PLC | N/A | 34.64M |
Related stock screener links
About 2EM.DE
Company Profile
Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey and currently employs 1,255 full-time employees. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm serves over 100 countries. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Companies subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.
Company Info
ERGOMED PLC
1 Occam Court, Occam Road
Guildford SURREY GB
Employees: 1255
Phone: 441483503205.0
ERGOMED PLC / 2EM.DE FAQ
Can you describe the business of ERGOMED PLC?
Ergomed Plc is a clinical stage development company, which provides specialist services to the pharmaceutical and biotechnology industries spanning all phases of clinical development, post-approval pharmacovigilance, and medical information. The company is headquartered in Guildford, Surrey and currently employs 1,255 full-time employees. The company went IPO on 2014-07-15. The firm operates through two segments: Clinical Research Services (CRO) and Pharmacovigilance (PV). Its CRO segment is the process of developing medical therapies, drugs and knowledge for safe use in healthcare. Its PV segment is engaged in the activities relating to the detection, understanding and prevention of adverse effects or other drug-related problems throughout its lifecycle. The firm serves over 100 countries. The company operates in North America, United Kingdom and Europe, Middle East and Africa, and Asia. The Companies subsidiaries include PrimeVigilance Inc., PrimeVigilance USA Inc., PrimeVigilance s.r.o., PharmInvent regulatory s.r.o., PrimeVigilance Japan K.K., Haemostatix Limited and Sound Opinion Limited.
What is the current price of 2EM stock?
The current stock price of 2EM.DE is 11 EUR. The price decreased by -3.68% in the last trading session.
What is the dividend status of ERGOMED PLC?
2EM.DE does not pay a dividend.
What is the ChartMill technical and fundamental rating of 2EM stock?
2EM.DE has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
Is ERGOMED PLC (2EM.DE) stock a good buy?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on 2EM.DE.
What is the employee count for 2EM stock?
ERGOMED PLC (2EM.DE) currently has 1255 employees.
2EM.DE Technical Analysis
2EM.DE Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to 2EM.DE. While 2EM.DE has a great health rating, its profitability is only average at the moment.
2EM.DE Financial Highlights
Over the last trailing twelve months 2EM.DE reported a non-GAAP Earnings per Share(EPS) of 0.33. The EPS increased by 16.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 10.31% | ||
| ROA | 11.58% | ||
| ROE | 17.68% | ||
| Debt/Equity | 0.02 |
2EM.DE Forecast & Estimates
12 analysts have analysed 2EM.DE and the average price target is 16.93 EUR. This implies a price increase of 53.9% is expected in the next year compared to the current price of 11.
For the next year, analysts expect an EPS growth of 15.11% and a revenue growth 12.58% for 2EM.DE